
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

AeroClean Technologies, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value per share
(Title of Class of Securities)

007744 105
(CUSIP Number)

N/A
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS David Helfet, M.D.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 759,590
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 759,590
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 759,590	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.5%*	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN	

* Based on 13,877,636 shares of common stock, par value \$0.01 per share ("Common Stock"), of AeroClean Technologies, Inc. (the "Issuer") outstanding as of March 28, 2022, as reported on the Issuer's Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the "SEC") on April 1, 2022.

CUSIP NO. 007744 105

Item 1(a) Name of Issuer:

AeroClean Technologies, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:

10455 Riverside Dr., Palm Beach Gardens, FL 33410

Item 2(a) Name of Persons Filing:

David Helfet, M.D.

Item 2(b) Address of Principal Business Office or, if none, Residence:

10455 Riverside Dr., Palm Beach Gardens, FL 33410

Item 2(c) Citizenship:

United States

Item 2(d) Title of Class of Securities:

Common stock, par value \$0.01 per share

Item 2(e) CUSIP No.:

007744 105

Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

This statement is not filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c).

Item 4 Ownership:

(a) Amount beneficially owned:

759,590

(b) Percent of class:

5.5%*

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

759,590

(ii) Shared power to vote or to direct the vote:

None

(iii) Sole power to dispose or to direct the disposition of:

759,590

(iv) Shared power to dispose or to direct the disposition of:

None

* Based on 13,877,636 shares of Common Stock outstanding as of March 28, 2022, as reported on the Issuer's Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on April 1, 2022.

Item 5 **Ownership of Five Percent or Less of a Class:**

Not applicable.

Item 6 **Ownership of More than Five Percent on Behalf of Another Person:**

Not applicable.

Item 7 **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:**

Not applicable.

Item 8 **Identification and Classification of Members of the Group:**

Not applicable.

Item 9 **Notice of Dissolution of Group:**

Not applicable.

Item 10 **Certifications:**

Not applicable.

CUSIP NO. 007744 105

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 4, 2022

By: /s/ David Helfet, M.D.
David Helfet, M.D.
